MétaCan
Menu
Back to cohort
Record W4417284745 · doi:10.1136/bmjopen-2025-107493

Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the <i>Staphylococcus aureus</i> Network Adaptive Platform (SNAP) randomised controlled trial

2025· article· en· W4417284745 on OpenAlexafffundabout
Emily G. McDonald, Matthew P. Cheng, Joshua S. Davis, Anna L. Goodman, Patrick R. Lawler, Julie Marsh, Dominik Mertz, Mical Paul, Jesús Rodríguez‐Baño, Deborah Siegal, Steven Y. C. Tong, Genevieve Walls, Todd C. Lee

Bibliographic record

VenueBMJ Open · 2025
Typearticle
Languageen
FieldMedicine
TopicAntimicrobial Resistance in Staphylococcus
Canadian institutionsUniversity of OttawaMcMaster UniversityOttawa HospitalMcGill UniversityMcGill University Health Centre
FundersHealth Research Council of New ZealandNational Institute of Allergy and Infectious DiseasesNational Health and Medical Research CouncilMedical Research CouncilNational Institutes of HealthStarship FoundationDepartment of Health and Social CareNational Medical Research CouncilZonMwCanadian Institutes of Health ResearchNational Institute for Health and Care Research
KeywordsDabigatranRandomized controlled trialProtocol (science)Adjunctive treatmentClinical trialMEDLINE

Abstract

fetched live from OpenAlex

Introduction Many patients receive oral anticoagulation for reduced stroke risk in atrial fibrillation or as treatment or prevention of venous thromboembolism. Oral factor Xa inhibitors (oral FXaI, eg, apixaban, edoxaban or rivaroxaban) are commonly prescribed for this indication. Dabigatran, an oral direct thrombin inhibitor, is similarly approved. In vitro and animal model evidence suggests that dabigatran also has direct effects on Staphylococcus aureus virulence and infection. Observational data have shown that dabigatran users are less likely to develop S. aureus bacteremia (SAB), and a small randomised controlled trial showed that dabigatran has anti- S. aureus effects when compared with low molecular weight heparins during bloodstream infection. We seek to answer whether dabigatran is superior to the oral FXaIs in achieving better SAB outcomes among patients who independently require oral anticoagulation. We report the intervention-specific protocol, embedded in an adaptive platform trial. Methods and analysis The S. aureus Network Adaptive Platform (SNAP) trial [ NCT05137119 ] is a pragmatic, randomised, multicentre adaptive platform trial that compares different SAB therapies for 90-day mortality rates. For this intervention (‘Dabi-SNAP’), patients receiving therapy with an oral FXaI will be randomised to continue as usual or to change to dabigatran as of the next scheduled dose. All subjects will receive standard of care antibiotics and/or antibiotics allocated through other active domains in the platform. As the choice of anticoagulant may not demonstrate large differences in mortality, a ranked composite of death and adverse outcomes (Desirability of Outcome Ranking, or DOOR) was chosen as the primary outcome. Ethics and dissemination The study is conditionally approved by the research ethics board of the McGill University Health Centre: identifier 2025-10900. Trial results will be published open access in a peer-reviewed journal and presented at a global infectious disease conference. The trial is registered at clinicaltrials.gov with the identifier NCT06650501 . Trial registration number NCT0665050 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.036
metaresearch head score (Gemma)0.050
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.058
Threshold uncertainty score0.195

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0360.050
Meta-epidemiology (narrow)0.0060.003
Meta-epidemiology (broad)0.0090.008
Bibliometrics0.0020.003
Science and technology studies0.0020.004
Scholarly communication0.0050.003
Open science0.0030.002
Research integrity0.0070.008
Insufficient payload (model declined to judge)0.0580.011

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.374
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueBMJ OpenSame topicAntimicrobial Resistance in StaphylococcusFrench-language works237,207